Physician profile
Maritza Irizarry
NPI 1477734531
$3,815.06
in general payments reported to CMS, 2019-2025
27 companies · $1,485 in 2025
The $1,485 reported for 2025 was more than what 98% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $654 · 2020: $50.54 · 2021: $394 · 2022: $79.90 · 2023: $431 · 2024: $721 · 2025: $1,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,637.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $396.15 | 2019-2024 | |
| Medtronic, INC. | $271.99 | 2025 | Synchromedii, Intellis Adaptivestim |
| Madrigal Pharmaceuticals | $270.80 | 2025 | Rezdiffra |
| Inspire Medical Systems, INC. | $262.20 | 2023-2025 | Inspire |
| Eisai INC. | $238.60 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $224.33 | 2021-2024 | Daybue |
| Boston Scientific Corporation | $172.11 | 2019 | |
| Merck Sharp & Dohme LLC | $167.86 | 2021-2025 | Vaxneuvance, Proquad, Enflonsia |
| Edwards Lifesciences Corporation | $160.82 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Impulse Dynamics (USA) INC. | $158.88 | 2025 | Optimizer |
| Biosense Webster, INC. | $144.65 | 2025 | Carto 3 |
| Amgen INC. | $142.91 | 2025 | |
| Stemline Therapeutics INC. | $142.23 | 2025 | Orserdu |
| Shire North American Group INC | $136.92 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $121.37 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $115.86 | 2020-2024 | Doc Band |
| Pfizer INC. | $112.85 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $107.55 | 2021 | |
| Phathom Pharmaceuticals, INC. | $107.17 | 2024 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $106.88 | 2019 | |
| Davol INC. | $74.45 | 2021 | |
| Abbott Laboratories | $43.45 | 2025 | Id Now Instrument |
| Ultragenyx Pharmaceutical INC. | $40.59 | 2021-2022 | |
| Sobi, INC | $34.94 | 2020 | |
| Seqirus USA INC | $26.56 | 2023-2024 | Flucelvax, Flucelvax Quadrivalent |
| Sanofi Pasteur INC. | $16.51 | 2022 | |
| Glaxosmithkline, LLC. | $16.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maritza Irizarry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.